Date: 2013-11-04
Type of information: Establishment of a new subsidiary in the EU
Company: Edmond de Rothschild Investment Partners (France)
Investors: Edmond de Rothschild Group (France), BPI France (France), insurance companies, retirement funds, public pension funds, social institution, other institutional investors
Amount: €192 million
Funding type:
Planned used: Through BioDiscovery 4, Edmond de Rothschild Investment Partners will lead investments in 15 to 20 life sciences companies across all stages of development. The investments will be made in therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies. The fund will invest up to €20 million per company, mainly in Europe.
Others: Edmond de Rothschild Investment Partners has announced the closing of its BioDiscovery 4 venture capital fund for European life science companies after raising €192 million (US$ 250 million), increasing by almost 25% its investment capacity compared to the size of its previous life science fund. With this closing the total funds raised by EdRIP for life sciences investments to about €450 million.
In the past thirteen years, Edmond de Rothschild Investment Partners has invested in 46 life science companies, through BioDiscovery 1, 2 and 3 funds. Its exit track includes 10 trade sales among which Endosense, Vessix Vascular, Novagali, Pangenetics, Novexel, Spine Next and U3 Pharma, and 10 IPOs, among which Regado Biosciences, EOS Imaging, MDX Health, Cellectis.
Therapeutic area:
